(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Ukrainian foreign minister appeals for funds for drones - 24 Masked Men Steal Renoir, Matisse and Cézanne Paintings Worth Over $10 Million in 3-Minute Heist
- 3Share your pick for the tree that you love for its novel magnificence!
- 4Are IDF reservists properly armed during post-war operations?
- 56 Hints to Upgrade Your Appeal, In addition to Your Outlook
- Giude to Best Web based Learning Stage
- Find Exemplary Scents: An Extensive Aide
- Step by step instructions to Keep up with Great Hand Cleanliness Before Handshakes
- How to watch ‘The Traitors’ U.K. Season 4 from the U.S.
- $30K Disability Scam Implodes After Surf Trip in Mexico
- 4 Sound blocking Earphones for Prevalent Sound and Solace
- Find the Insider facts of Viable Advertising: Building a Positive Brand Picture
- Scientists sent a menstrual cup to space. This is how it went
- People who talk with their hands seem more clear and persuasive – new research
